

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

INSIDE INFORMATION

COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

References are made to (i) the announcement of the Company dated June 6, 2025 in relation to the application for the H share full circulation by the Company; (ii) the announcement of the Company dated January 23, 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company; and (iii) the announcement of the Company dated February 12, 2026 in relation to the grant of listing approval by the Stock Exchange for the implementation of the H share full circulation (collectively, the “**Announcements**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board of the Company is pleased to announce that the conversion of 4,608,000 Unlisted Shares into H shares had been completed on March 4, 2026, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on March 5, 2026.

SHAREHOLDING STRUCTURE

Immediately before and upon completion of the Conversion and the Listing, the share capital structure of the Company is as follows:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and the Listing	
	<i>Number of shares</i>	<i>Approximate percentage %</i>	<i>Number of shares</i>	<i>Approximate percentage %</i>
H shares	375,457,818	98.79%	380,065,818	100.00%
Unlisted shares	4,608,000	1.21%	—	—
Total	380,065,818	100.00%	380,065,818	100.00%

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, March 4, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.